abstract |
The invention relates to the use of dopamine autoreceptor agonists, in particular 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo [4,5-d] azepine (BHT 920) and (S) -2-Amino-4,5,6,7-tetrahydro-6-n-propylamino-benzothiazole (SND 919), for the manufacture of drugs for the treatment of drug addiction. |